Boyce Sarah
SEC CIK 1629383 · EDGAR
BoughtSold
Most active insiders at RNA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Younis Husam | CSO | — | — |
| 2 | Hoyos Rocio Martin | Chief Strategy Off | — | — |
| 3 | Winslow Brendan R. | CFO | — | — |
| 4 | Kenney Stephanie | See Remarks | — | — |
| 5 | Gallagher Kathleen P. | See Remarks, Dir | — | — |
| 6 | Flanagan W. Michael | Dir | — | — |
| 7 | Hughes Steven George | Chief Medical Off | — | — |
| 8 | Boyce Sarah | Dir | — | — |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-22 16:20 | 2026-09-18 | RNA | Atrium Therapeutics, Inc. | Boyce Sarah | Dir | F - Tax | $8.95 | -126.4K | 138.7K | -48% | -$1.13M | |
| D | 2024-06-21 | 2024-06-18 | OABI | OmniAb, Inc. | Boyce Sarah | Dir | M - OptEx | — | +20.0K | 68.4K | +41% | — |
| A | 2024-04-23 | 2022-11-01 | OABI | OmniAb, Inc. | Boyce Sarah | Dir | A - Grant | — | +39.6K | 48.4K | +453% | — |
| D | 2023-02-01 | 2023-01-30 | OABI | OmniAb, Inc. | Boyce Sarah | Dir | A - Grant | $0.00 | +8,753 | 46.2K | +23% | $0 |
| MI | 2022-11-14 | 2022-11-09+ | OABI | OmniAb, Inc. | Boyce Sarah | Dir | P - Purchase | $2.81 | +36.0K | 21.0K | New | +$101.3K |
| D | 2022-11-03 | 2022-11-01 | LGND | LIGAND PHARMACEUTICALS INC | Boyce Sarah | Former Dir | D - Sale to Iss | — | -1,004 | 2,892 | -26% | — |
| D | 2022-11-03 | 2022-11-01 | OABI | OmniAb, Inc. | Boyce Sarah | Dir | A - Grant | — | +37.4K | 37.4K | New | — |
| D | 2022-06-13 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Boyce Sarah | Dir | A - Grant | $0.00 | +1,004 | 3,896 | +35% | $0 |
Purchase Sale Sale after option exercise All abbreviations